
In this Q&A-style podcast, Kristoff Rademan, Chief Financial Officer of UK fabless semiconductor company, EnSilica, explains how EnSilica moved from design consultancy to designing and supplying its own chips, and then listing on the London Stock Exchange’s ‘junior’ market, AIM.
He talks about his move from group financial controller at Oxford Biomedica, the company that made the AstraZeneca COVID vaccine, to his first CFO role in an industry he knew nothing about.
Kristoff then explains why EnSilica decided to list on AIM in the middle of the pandemic and how AIM compares with the FTSE and NASDAQ. He also describes how chip economics work, how investor sentiment to chip companies has turned in the last year, and the company’s goal of becoming Europe’s leading fabless chip company: “a mini-Marvell.”
This podcast is also available on the BritChips YouTube channel and in audio form on Apple Podcasts and Spotify.
Topics covered
* How EnSilica operates.
* The move from group controller to CFO.
* Why smaller companies can be quicker and more innovative.
* Employee growth.
* Why a listed company needs a CFO.
* Ways to fund growth: loans vs private equity vs IPO.
* Listing on AIM during COVID.
* AIM, FTSE and NASDAQ compared.
* The economics of chip design and supply.
* Why space is a growth market for EnSilica.
* Investor sentiment in chip stocks.
* A wish list for policy makers.
* What’s next: EnSilica’s growth aspirations.
Timings (approx)
00:00 – EnSilica’s 25-year journey from consultancy to chip company
01:10 – The three parts of the business
02:38 – From Oxford Biomedica to CFO
04:36 – Taking on a CFO role in a new industry
05:29 – Team growth and the new Italian design centre
06:00 – Why a listed company needs a CFO
07:45 – Ways to fund growth: loans, private equity or an IPO
09:56 – Listing on AIM during COVID
11:09 – AIM vs FTSE vs NASDAQ
11:58 – The IPO raise and the economics of chips
12:57 – The low-Earth-orbit satellite modem
14:42 – How investor sentiment has changed
16:13 – Pension funds and UK growth capital
17:05 – Growth plans and becoming “a mini-Marvell”
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit anttheantidote.substack.com
More episodes from "The BritChips Podcast"



Don't miss an episode of “The BritChips Podcast” and subscribe to it in the GetPodcast app.








